Trial Profile
A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Pharmacodynamics
- Sponsors Alexion Pharmaceuticals
- 06 Apr 2021 Results assessing the PK of asfotase alfa in adult patients with pediatric onset hypophosphatasia following administration of a range of dose regimens that encompasses the dose proven to be effective in pediatric patients (i.e., 6.0 mg/kg/wk), published in the Journal of Clinical Pharmacology
- 20 Mar 2018 Results assessing dose response study of Asfotase Alfa, presented at The 100th Annual Meeting of the Endocrine Society.
- 11 Sep 2017 Status changed from active, no longer recruiting to completed.